logo
  Join        Login             Stock Quote

Pfizer (PFE): Lyrica Nerve-Pain Treatment Fails In Diabetes Study, Stops HIV Trial

 May 04, 2012 10:11 AM
 


(By Balachander) Pfizer Inc. (NYSE:PFE) said a late-stage trial of its Lyrica nerve-pain treatment failed to meet main objective of a specified change in pain and said it stopped a similar study involving patients with HIV neuropathy.

The company's phase 3 trial tested Lyrica in patients suffering with diabetes-related nerve damage.

Meanwhile, an interim analysis of a similar study in patients with neuropathic pain associated with HIV neuropathy showed that the improvements in neuropathic pain symptoms were virtually same between the Lyrica and placebo treatments.

Lyrica is not approved in the U.S. for the treatment of neuropathic pain associated with HIV neuropathy. Sales of Lyrica grew 16 percent to $955 million in the first quarter.

[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]

Pharmaceutical companies like Pfizer are seeking to expand use of current drugs to offset the loss of patents on key drugs.

In the United States, Lyrica capsules CV is approved to treat diabetic nerve pain, pain after shingles, fibromyalgia and partial onset seizures in adults with epilepsy who take one or more drugs for seizures.

Painful diabetic peripheral neuropathy is a form of nerve damage characterized by burning pain, pins and needles, or shooting pain in the feet and often in the hands as well. Around 20 percent of people with diabetes experience pain resulting from nerve damage, Pfizer noted.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageMBIA Inc. (MBI) : BTI's $12 a Tough Task

MBIA Inc. (NYSE:MBI) is doing well on a day stocks are struggling The guarantee insurance company is the read on...

article imageUrban Outfitters, Inc. (URBN) Q2 Earnings Preview: A Snug Fit

Urban Outfitters, Inc. (NASDAQ:URBN) will hold a webcast to discuss its second quarter of fiscal-year 2015 read on...

article imageEstee Lauder Companies Inc. (EL) Q4 Earnings Preview: Options Player Betting On EL’s EPS Looking Pretty

Estee Lauder Companies Inc. (NYSE:EL) will release fiscal 2014 fourth quarter and full year financial read on...

article imageHerbalife Ltd. (HLF): 3 Reasons To Pay Attention to Recent Insider Buying

Well, well, well… it looks as if boardroom buyers viewed the recent selloff as an opportunity to buy. read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.